Syon Capital LLC Acquires 111 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Syon Capital LLC lifted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,276 shares of the pharmaceutical company’s stock after purchasing an additional 111 shares during the period. Syon Capital LLC’s holdings in Vertex Pharmaceuticals were worth $926,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the stock. Venturi Wealth Management LLC raised its holdings in Vertex Pharmaceuticals by 1.1% in the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after purchasing an additional 24 shares during the period. Nicholas Hoffman & Company LLC. increased its position in shares of Vertex Pharmaceuticals by 3.9% in the 4th quarter. Nicholas Hoffman & Company LLC. now owns 636 shares of the pharmaceutical company’s stock valued at $259,000 after buying an additional 24 shares in the last quarter. Arthur M. Cohen & Associates LLC raised its stake in Vertex Pharmaceuticals by 3.2% during the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after buying an additional 25 shares during the period. Baystate Wealth Management LLC lifted its holdings in Vertex Pharmaceuticals by 49.0% during the fourth quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock worth $31,000 after acquiring an additional 25 shares in the last quarter. Finally, Arjuna Capital grew its stake in Vertex Pharmaceuticals by 0.7% in the third quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock valued at $1,521,000 after acquiring an additional 29 shares during the period. Institutional investors own 90.96% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Vertex Pharmaceuticals from $390.00 to $438.00 and gave the stock an “overweight” rating in a research report on Thursday, February 1st. Guggenheim lifted their price target on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, April 18th. Robert W. Baird downgraded shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective for the company. in a research report on Wednesday, January 31st. Barclays boosted their price objective on shares of Vertex Pharmaceuticals from $446.00 to $472.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. Finally, Royal Bank of Canada increased their target price on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a report on Tuesday, February 6th. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock traded down $3.06 during trading hours on Thursday, reaching $397.70. The company’s stock had a trading volume of 787,274 shares, compared to its average volume of 1,234,807. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a fifty-two week low of $316.43 and a fifty-two week high of $448.40. The company has a market capitalization of $102.79 billion, a price-to-earnings ratio of 28.85, a PEG ratio of 1.91 and a beta of 0.35. The firm’s 50 day simple moving average is $412.66 and its 200-day simple moving average is $398.38.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The business had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter in the prior year, the firm earned $3.33 EPS. Sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Insiders Place Their Bets

In other news, EVP Amit Sachdev sold 3,222 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the completion of the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 480 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $420.79, for a total value of $201,979.20. Following the transaction, the executive vice president now owns 59,827 shares in the company, valued at $25,174,603.33. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,381 shares of company stock worth $5,203,249. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.